Recent Publications

Recent publications on Mucosis’ technology and vaccine programs are listed below.

Development of a multiplexed bead-based immunoassay for the simultaneous detection of antibodies to 17 pneumococcal proteins. S. Shoma, N.J. Verkaik, C.P. de Vogel, P.W.M. Hermans, S. van Selm, T.J. Mitchell, M. van Roosmalen, S. Hossain, M. Rahman, H.Ph. Endtz, W.J. B. van Wamel, A. van Belkum. Eur. J. Clin. Microbiol. Infect. Dis. 30 (2011):521-526.

Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. V. Saluja, M.R. Visser,W. ter Veer, M.L. van Roosmalen, K. Leenhouts, W.L.J. Hinrichs, A. Huckriede, H.W. Frijlink. Vaccine 28 (2010):7963-7969.

Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive Enhancer Matrix (GEM) particles. V. Saluja, M.R. Visser, M.L. van Roosmalen, K. Leenhouts, A. Huckriede, W.L.J. Hinrichs, H.W. Frijlink. Eur. J. Pharm. Biopharm. 76 (2010):470-474.

Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. V. Saluja, J.P. Amorij, M.L. van Roosmalen, K. Leenhouts, A. Huckriede, W.L.J. Hinrichs, H.W. Frijlink. AAPS J. 12 (2010):109-116.

read more >

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >

21.03.11 Mucosis starts clinical study with its lead product, Flugem®
more >

12.11.10 Dr. Barry Buckland joins the Mucosis supervisory board
more >

28.09.10 Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines
more >